Literature DB >> 29095966

Systematic screening for atrial fibrillation in a 65-year-old population with risk factors for stroke: data from the Akershus Cardiac Examination 1950 study.

Trygve Berge1,2, Jon Brynildsen2,3, Hege K Netmangen Larssen3, Sophia Onarheim1, Gaute R Jenssen1,2, Haakon Ihle-Hansen1,2, Ingrid E Christophersen1, Marius Myrstad1, Helge Røsjø2,3, Pål Smith2,3, Arnljot Tveit1,2.   

Abstract

Aims: To investigate the yield of screening for atrial fibrillation (AF) in a cohort of 65-year-old individuals from the general population with additional risk factors for stroke. Methods and results: We invited participants with additional risk factors for stroke (CHA2DS2-VASc score ≥2 for men or ≥ 3 for women) without previously known AF from a population-based study in Norway to participate in a 2-week screening for AF. Screening was performed by one-lead 'thumb electrocardiography (ECG)' recordings of 30 s twice daily or when the participants experienced symptoms. In total, 1742 (47.0%) participants of the Akershus Cardiac Examination (ACE) 1950 study had at least one additional risk factor for stroke. Of these, 123 cases reported a history of AF and 101 (5.8%) cases were ECG validated. Eight [0.5%, 95% confidence interval (CI) 0.2-0.9] new AF cases were diagnosed by 12-lead ECG at baseline, and 10 additional participants were diagnosed with AF before screening commenced. We invited all 1601 participants who met the inclusion criteria for screening, of which 1510 (94.3%) participants were included (44% women and 56% men). The screening revealed AF in 13 (0.9%, 95% CI 0.5-1.5) participants. The total prevalence of ECG-validated AF after screening among the 65-year-olds with risk factors for stroke was 7.6% (95% CI 6.4-8.9), in men 10.0% (95% CI 8.2-12.0), and in women 4.3% (95% CI 3.0-6.1) (P < 0.001).
Conclusion: In a group of 1510 well-characterized 65-year-olds with risk factors for stroke, 2-week intermittent ECG screening identified undiagnosed AF in 0.9%. The total prevalence of AF was 7.6%.

Entities:  

Mesh:

Year:  2018        PMID: 29095966     DOI: 10.1093/europace/eux293

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  7 in total

1.  Improving Knowledge and Early Detection of Atrial Fibrillation through a Community-Based Opportunistic Screening Program: What's Your Beat?

Authors:  Abubakar Ibrahim Jatau; Luke R Bereznicki; Barbara C Wimmer; Woldesellassie M Bezabhe; Gregory M Peterson
Journal:  Int J Environ Res Public Health       Date:  2022-06-03       Impact factor: 4.614

Review 2.  Screening for Atrial Fibrillation in Community and Primary CareSettings: A Scoping Review.

Authors:  Emma Canty; Claire MacGilchrist; Wael Tawfick; Caroline McIntosh
Journal:  J Atr Fibrillation       Date:  2021-02-28

Review 3.  Emerging Technologies for Identifying Atrial Fibrillation.

Authors:  Eric Y Ding; Gregory M Marcus; David D McManus
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 23.213

4.  Braden scale for assessing pneumonia after acute ischaemic stroke.

Authors:  Yunlong Ding; Yazhou Yan; Jiali Niu; Yanrong Zhang; Zhiqun Gu; Ping Tang; Yan Liu
Journal:  BMC Geriatr       Date:  2019-10-07       Impact factor: 3.921

Review 5.  Large-scale screening studies for atrial fibrillation - is it worth the effort?

Authors:  J Engdahl; M Rosenqvist
Journal:  J Intern Med       Date:  2021-01-07       Impact factor: 8.989

6.  Patient-reported feasibility of chest and thumb ECG after cryptogenic stroke in Sweden: an observational study.

Authors:  Peter Magnusson; Adam Lyren; Gustav Mattsson
Journal:  BMJ Open       Date:  2020-10-28       Impact factor: 2.692

7.  Opportunistic screening versus usual care for detection of atrial fibrillation in primary care: cluster randomised controlled trial.

Authors:  Steven B Uittenbogaart; Nicole Verbiest-van Gurp; Wim A M Lucassen; Bjorn Winkens; Mark Nielen; Petra M G Erkens; J André Knottnerus; Henk C P M van Weert; Henri E J H Stoffers
Journal:  BMJ       Date:  2020-09-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.